Introduction
The HAS-BLED score is a clinical prediction tool used to estimate a patient’s one-year risk of major bleeding while on oral anticoagulation, most commonly in the context of atrial fibrillation. It works by assigning one point (occasionally two) for each of nine clinical risk factors captured in its acronym: Hypertension, Abnormal renal or liver function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly (age over 65), and Drugs or alcohol use. The resulting total, from 0 to 9, helps clinicians identify patients who need closer monitoring or correction of modifiable bleeding risks before or during anticoagulant therapy.
The tool was developed by Pisters and colleagues in 2010 from the Euro Heart Survey and has since become one of the two scores routinely used together in AF management, alongside the CHA₂DS₂-VASc score for stroke risk [1,2]. It is used mainly by cardiologists, hematologists, and primary care physicians when starting or reviewing anticoagulation, and increasingly by pharmacists during medication reviews. The HAS-BLED score is a useful example of balancing two competing risks, stroke prevention against bleeding, rather than simply screening for one disease.
The HAS-BLED Criteria
| Letter | Clinical Feature | Points |
|---|---|---|
| H | Hypertension (uncontrolled, systolic blood pressure > 160 mmHg) | 1 |
| A | Abnormal renal function (dialysis, transplant, or creatinine ≥ 2.3 mg/dL / 200 µmol/L) or abnormal liver function (cirrhosis, or bilirubin > 2x normal with AST/ALT/ALP > 3x normal) | 1 (renal) + 1 (liver), max 2 |
| S | Stroke history | 1 |
| B | Bleeding history or predisposition (e.g., prior major bleed, anemia, bleeding diathesis) | 1 |
| L | Labile INR (time in therapeutic range < 60% in patients on warfarin) | 1 |
| E | Elderly (age > 65 years) | 1 |
| D | Drugs (concomitant antiplatelet agents or NSAIDs) or alcohol (≥ 8 drinks per week) | 1 (drugs) + 1 (alcohol), max 2 |
Because the “A” and “D” categories can each contribute up to 2 points, the maximum possible score is 9, even though there are only 7 letters in the acronym.
Modern clinical guidelines, including those from the European Society of Cardiology (ESC), emphasize that clinicians should mentally categorize these criteria to direct patient care. The components are classified into Modifiable (Hypertension, Labile INR, Drugs, Alcohol), Potentially Modifiable (Abnormal renal/liver function, anemia/bleeding predisposition), and Non-Modifiable (Elderly, Stroke history) factors [4]. By isolating the modifiable targets, clinicians can actively work to lower a patient's score over time.
HAS-BLED Score Calculator
HAS-BLED Score Calculator
Estimate 1-year major bleeding risk in atrial fibrillation
Total Score: 0 / 9
Estimated rate of ~1 to 1.9 bleeds per 100 patient-years.
Interpreting the HAS-BLED Score
The total score correlates with the estimated rate of major bleeding per 100 patient-years, where major bleeding is defined as intracranial hemorrhage, bleeding requiring hospitalization, a hemoglobin drop of more than 2 g/dL, or bleeding requiring transfusion [1,3].
| Score | Approximate Risk Category | Bleeding Rate |
|---|---|---|
| 0–1 | Low risk | ~1–1.1 bleeds per 100 patient-years |
| 2 | Moderate risk | ~1.9 bleeds per 100 patient-years |
| 3 | High risk | ~3.7 bleeds per 100 patient-years |
| ≥ 4 | High risk | ~8.7+ bleeds per 100 patient-years |
Most guidelines simplify this into two practical categories: 0–2 = lower risk, ≥ 3 = high risk, prompting closer follow-up [2,3].
A high HAS-BLED score is not, by itself, a reason to withhold anticoagulation. In atrial fibrillation, the risk of ischemic stroke without anticoagulation usually outweighs the bleeding risk, even in high-scoring patients. The score’s real purpose is to flag modifiable risk factors, uncontrolled blood pressure, concurrent NSAID use, unstable INR control, or heavy alcohol intake, so they can be corrected, allowing the patient to stay on anticoagulation more safely rather than being taken off it. This distinguishes HAS-BLED from a simple “yes/no” gatekeeping test.
Case Scenarios
Scenario 1: Low risk, straightforward anticoagulation
A 58-year-old man with atrial fibrillation has well-controlled blood pressure, normal renal and liver function, no bleeding or stroke history, and does not drink alcohol or take NSAIDs.
Calculator Exercise: What is his total score?
Clinical Interpretation: 0 across all categories = HAS-BLED score = 0 → low risk. He is started on a DOAC with routine follow-up.
Scenario 2: Moderate risk with a modifiable factor
A 72-year-old woman with atrial fibrillation has a systolic blood pressure of 168 mmHg despite treatment, and takes ibuprofen occasionally for joint pain. She has normal renal and liver function and no bleeding or stroke history.
Calculator Exercise: What is her total score?
Clinical Interpretation: uncontrolled hypertension (+1), elderly > 65 (+1), NSAID use (+1) = HAS-BLED score = 3 → high risk. Rather than withholding anticoagulation, her care team intensifies blood pressure control and switches her joint pain management away from NSAIDs, which can meaningfully lower her modifiable bleeding risk at the next review.
Scenario 3: High risk requiring closer monitoring
A 78-year-old man on warfarin for atrial fibrillation has chronic kidney disease (creatinine 2.5 mg/dL), a prior gastrointestinal bleed, and a time-in-therapeutic-range of only 45% on his INR checks. He also drinks around 10 alcoholic drinks per week.
Calculator Exercise: What is his total score?
Clinical Interpretation: abnormal renal function (+1), bleeding history (+1), labile INR (+1), elderly (+1), alcohol (+1) = HAS-BLED score = 5 → high risk. His team considers switching him from warfarin to a DOAC (which removes the labile INR issue), refers him for alcohol counseling, and schedules more frequent follow-up, while continuing anticoagulation given his significant stroke risk from atrial fibrillation.
Limitations of the HAS-BLED Score
Because HAS-BLED was derived in 2010 when warfarin was the standard of care, its calibration is slightly altered in the modern era where Direct Oral Anticoagulants (DOACs) are the preferred first-line therapy. For patients on DOACs, the "L" (Labile INR) factor is irrelevant and automatically scores zero. Because of this shift, recent North American guidelines, including the 2023 ACC/AHA/ACCP/HRS guidelines, now endorse the ORBIT bleeding score as an alternative or preferred tool, noting it often provides superior predictive accuracy for patients taking DOACs [3,5].
The score was also derived and validated primarily in atrial fibrillation populations, so its accuracy in other anticoagulated groups, such as patients treated for VTE, is less well established. Like other risk scores in this series, HAS-BLED is a decision aid, not a decision-maker: it should inform a conversation about risk and modifiable factors, not automatically dictate whether a patient receives anticoagulation.
Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.
References
- Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J., & Lip, G. Y. (2010). A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 138(5), 1093–1100. https://doi.org/10.1378/chest.10-0134
- Lip G. Y. (2011). Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. The American journal of medicine, 124(2), 111–114. https://doi.org/10.1016/j.amjmed.2010.05.007
- Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., Gorenek, B., Hess, P. L., Hlatky, M., Hogan, G., Ibeh, C., Indik, J. H., Kido, K., Kusumoto, F., Link, M. S., Linta, K. T., … Peer Review Committee Members (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1–e156. https://doi.org/10.1161/CIR.0000000000001193
- Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G. A., Dilaveris, P. E., Fauchier, L., Filippatos, G., Kalman, J. M., La Meir, M., Lane, D. A., Lebeau, J. P., Lettino, M., Lip, G. Y. H., Pinto, F. J., Thomas, G. N., … ESC Scientific Document Group (2021). 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal, 42(5), 373–498. https://doi.org/10.1093/eurheartj/ehaa612
- O'Brien, E. C., Simon, D. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., Kowey, P. R., Mahaffey, K. W., Chang, P., Fonarow, G. C., Pencina, M. J., Piccini, J. P., & Peterson, E. D. (2015). The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European heart journal, 36(46), 3258–3264. https://doi.org/10.1093/eurheartj/ehv476
